Business Wire

Rigaku Joins Two Partners in Establishing RIGAKU/JEOL-iCeMS Innovation Core and Concluding a Cooperation Agreement

4.9.2025 16:00:00 CEST | Business Wire | Press Release

Share

On September 4, 2025, Rigaku Corporation, a global solution partner in X-ray analytical systems and a Group company of Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; President & CEO: Jun Kawakami; hereinafter “Rigaku”); Kyoto University (Main campus: Kyoto; Nagahiro Minato, President; hereinafter “Kyoto University”); and JEOL Ltd. (headquarters: Akishima, Tokyo; President & CEO: Izumi Oi, hereinafter “JEOL”) concluded an agreement to establish an organization for open innovation. The purpose of this initiative is to leverage each other’s strengths, conduct joint research and development and cultivate skilled personnel.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250904601877/en/

RIGAKU/JEOL-iCeMS Innovation Core

The newly established RIGAKU/JEOL-iCeMS Innovation Core is a joint research facility founded within the Analysis Center of the Institute for Integrated Cell-Material Sciences (Kyoto University iCeMS).

RIGAKU/JEOL-iCeMS Innovation Core will apply innovative methods of molecular-structure analysis, centering on electron-beam diffraction of nanocrystals. In particular, the joint research facility will furnish a measurement environment to accelerate the search for functions in new materials, using tools such as XtaLAB Synergy-ED. (XtaLAB Synergy-ED is a radically new electron diffraction and integration platform that integrates Rigaku’s monocrystal X-ray structural-analysis technology with JEOL’s transmission electron microscopy technology.)

In this way RIGAKU/JEOL-iCeMS Innovation Core aims to advance basic research, return research results to society and cultivate skilled personnel, thereby contributing to innovation through academic-industrial partnership.

RIGAKU/JEOL-iCeMS Innovation Core is an R&D facility dedicated to the advancement of material science through open innovation. Focusing on nanocrystal materials discovered through partnership between academia and industry, RIGAKU/JEOL-iCeMS Innovation Core aims to build a platform to elucidate the relationships between structure and function of these materials and develop applications for them.

Overview of the agreement and joint research facility

Agreement period: From September 4, 2025 to March 31, 2028

Contract renewal possible

Overview of joint research facility: RIGAKU/JEOL-iCeMS Innovation Core

Joint research facility founded within iCeMS Analysis Center, Kyoto University

Comments
Jun Kawakami
President & CEO, Rigaku
I am delighted that Rigaku was able to join Kyoto University and JEOL in establishing this new research and development base. Since its foundation, Rigaku has proudly contributed to scientific progress through advancements in structural-analytical technology. Through the use of electron diffraction of nanocrystals, RIGAKU/JEOL-iCeMS Innovation Core will accelerate the development of this technology and research in its applications. We look forward to returning the knowledge obtained through this academic-industrial partnership to the broader society and using it to develop the next generation of skilled personnel on whom the future depends.

Nagahiro Minato
President, Kyoto University
With the foundation of RIGAKU/JEOL-iCeMS Innovation Core, these three partners—Rigaku, JEOL and Kyoto University—have joined hands to advance leading-edge research and development through open innovation. This initiative is one of great importance, as it dovetails with the University’s orientation to ally with analytical-device manufacturers on the concept of a core facility for Kyoto University under the plan for the University for International Research Excellence. We have high expectations that this effort will lead to strengthened research, innovation and development of outstanding personnel. Moreover, the results of this project will underpin the scientific, technological and industrial foundations not only of the three partners but of Japan in general, and will support breakthroughs in finding solutions to issues confronting society. Kyoto University will expend every effort to ensure the success of RIGAKU/JEOL-iCeMS Innovation Core.

Izumi Oi
President & CEO, JEOL
The establishment of RIGAKU/JEOL-iCeMS Innovation Core in partnership with Kyoto University and Rigaku is a vital initiative toward equipping society with revolutionary structural-analytical technologies. By developing electron diffractometers applying transmission electron microscopy technology, JEOL looks forward to advancing the structural analysis of nanocrystals and accelerating the elucidation of functions of new materials. Through the technological innovations advanced through these efforts and the products and technologies they generate, RIGAKU/JEOL-iCeMS Innovation Core will support applied research in a wide range of fields, including life sciences, the environment, energy and more, contributing to scientific progress and social development.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250904601877/en/

Contacts

Press Contact:
Sawa Himeno
Head of Communications Dept., Rigaku Holdings Corporation
prad@rigaku.co.jp
Tel: +81 90 6331 9843

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye